Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort

被引:95
作者
Sieri, Sabina [1 ]
Krogh, Vittorio [1 ]
Bolelli, Gianfranco [7 ]
Abagnato, Carlo Alberto [7 ]
Grioni, Sara [1 ]
Pala, Valeria [1 ]
Evangelista, Alberto [1 ]
Allemani, Claudia [2 ]
Micheli, Andrea [3 ]
Tagliabue, Giovanna [4 ]
Schunemann, Holger J. [8 ]
Menard, Sylvie [5 ]
Berrino, Franco [6 ]
Muti, Paola [8 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Nutr Epidemiol Unit, I-20133 Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Analyt Epidemiol Unit, I-20133 Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Descript Epidemiol & Hlth Planning Unit, I-20133 Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Canc Registry Div, I-20133 Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Labs & Dept Expt Oncol, Mol Biol Unit, I-20133 Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Etiol & Prevent Epidemiol Unit, I-20133 Milan, Italy
[7] Ctr Med Diagnost Emilia, Bologna, Italy
[8] Ist Regina Elena, Epidemiol & Prevent Unit, I-00161 Rome, Italy
关键词
METABOLIC-SYNDROME; ESTROGEN-RECEPTOR; GENE-EXPRESSION; ENDOGENOUS ESTROGENS; PROGESTERONE; ANDROGEN; TESTOSTERONE; CARCINOMAS; GROWTH;
D O I
10.1158/1055-9965.EPI-08-0808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endogenous sex hormone levels have been associated with increased breast cancer risk in postmenopausal women in several prospective studies. However, it remains unclear to what extent serum hormone-breast cancer associations differ with receptor status. Methods: Associations between serum sex hormone levels and breast cancer risk were assessed in a nested case-control study on postmenopausal women of the ORDET cohort. After a median follow-up of 13.5 years, 1.65 women developed breast cancer. Relative risks of developing breast cancer were estimated by conditional logistic regression. Results: Total and free testosterone levels were directly associated with breast cancer risk [relative risk, 3.28 (95% confidence interval, 1.93-5.55) and 2.86 (95% confidence interval, 1.66-4.94), respectively, for highest versus lowest quartile]. When relations between hormone level and risk of breast cancer expressing various receptor combinations were assessed, high total testosterone was significantly associated with increased risk of estrogen receptor-positive cancers, irrespective of progesterone receptor status. High total testosterone was also associated with increased risk of both human epidermal growth factor receptor 2 (HER2)-negative (HER2(-)) and HER2(+) cancers. High estradiol tended to be associated with increased risk of HER2- cancer and inversely associated with HER2(+) cancer, with significant (P = 0.027) heterogeneity between HER2(+) and HER2- cancers. However, there were relatively few HER2(+) cases. Conclusions: This study provides further evidence that high levels of circulating testosterone increase the risk of developing breast cancer in postmenopausal women. The cancers that develop are mainly estrogen receptor positive. Although HER2(+) and HER2- breast cancers were both associated with high total testosterone, they showed opposing associations with estrogen. (Cancer Epidemiol Biomarkers Prev 2009;18(1):169-76)
引用
收藏
页码:169 / 176
页数:8
相关论文
共 40 条
  • [31] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER
    SLAMON, DJ
    GODOLPHIN, W
    JONES, LA
    HOLT, JA
    WONG, SG
    KEITH, DE
    LEVIN, WJ
    STUART, SG
    UDOVE, J
    ULLRICH, A
    PRESS, MF
    [J]. SCIENCE, 1989, 244 (4905) : 707 - 712
  • [32] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
    SLAMON, DJ
    CLARK, GM
    WONG, SG
    LEVIN, WJ
    ULLRICH, A
    MCGUIRE, WL
    [J]. SCIENCE, 1987, 235 (4785) : 177 - 182
  • [33] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
  • [34] A PROSPECTIVE-STUDY OF ENDOGENOUS ESTROGENS AND BREAST-CANCER IN POSTMENOPAUSAL WOMEN
    TONIOLO, PG
    LEVITZ, M
    ZELENIUCHJACQUOTTE, A
    BANERJEE, S
    KOENIG, KL
    SHORE, RE
    STRAX, P
    PASTERNACK, BS
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (03): : 190 - 197
  • [35] Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer
    Vona-Davis, L.
    Howard-McNatt, M.
    Rose, D. P.
    [J]. OBESITY REVIEWS, 2007, 8 (05) : 395 - 408
  • [36] Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women
    Weinberg, Melissa E.
    Manson, JoAnn E.
    Buring, Julie E.
    Cook, Nancy R.
    Seely, Ellen W.
    Ridker, Paul M.
    Rexrode, Kathryn M.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (11): : 1473 - 1480
  • [37] Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence
    Xue, Fei
    Michels, Karin B.
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 86 (03) : 823S - 835S
  • [38] Yoo KY, 1997, AM J EPIDEMIOL, V146, P307, DOI 10.1093/oxfordjournals.aje.a009271
  • [39] Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
    Zeleniuch-Jacquotte, A
    Shore, RE
    Koenig, KL
    Akhmedkhanov, A
    Afanasyeva, Y
    Kato, I
    Kim, MY
    Rinaldi, S
    Kaaks, R
    Toniolo, P
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 153 - 159
  • [40] ZELENIUCHJACQUOTTE A, 1995, CANCER EPIDEM BIOMAR, V4, P857